

Finasteride (1%) Formulation

Version 9.1	Revision Date: 30.09.2023		S Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
SECTIO	N 1. PRODUCT AND C	OMPA	NY IDENTIFICAT	ION
Product name		:	Finasteride (1%)	Formulation
Mai	nufacturer or supplier'	's detai	ils	
	npany	:	Organon & Co.	
Add	iress	:	Rua Treze de Ma Campinas, São I	aio, 1161 Paulo, Brazil 13106-054
Tele	ephone	:	+55 (19) 3758-20	000
Emo	ergency telephone	:	+55 (11) 3173-49	931
E-m	E-mail address		EHSSTEWARD	@organon.com
Rec	commended use of the	e chem	ical and restriction	ons on use
	commended use trictions on use	:	Pharmaceutical Not applicable	

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accord Reproductive toxicity		ce with ABNT NBR 14725 Standard Category 1B
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Testis)
Long-term (chronic) aquatic hazard	:	Category 3
GHS label elements in accor	daı	nce with ABNT NBR 14725 Standard
Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	H360D May damage the unborn child. H373 May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed. H412 Harmful to aquatic life with long lasting effects.
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P260 Do not breathe dust. P273 Avoid release to the environment.

Version

9.1



Date of last issue: 04.04.2023

Date of first issue: 26.01.2015

Finasteride (1%) Formulation

Revision Date:

30.09.2023

			P280 Wear protective gloves/ protective clothing/ eye protec- tion/ face protection.			
		Response:	Response:			
		•	P308 + P313 IF exposed or concerned: Get medical advice/			
		Storage:				
		P405 Store	lookod un			
		F405 Store	lockeu up.			
	Other hazards which do not r	esult in classif	ication			
	Dust contact with the eyes can	lead to mechan	ical irritation.			
	Contact with dust can cause me					
	May form explosive dust-air mix			r means.		
05						
SEC	CTION 3. COMPOSITION/INFO		NGREDIENIS			
	Substance / Mixture	: Mixture				
		. Mixture				
	Components					
	Chemical name	CAS-No.	Classification	Concentration (% w/w)		
	Cellulose	9004-34-6		>= 5 -< 10		
	Starch	9005-25-8		>= 5 -< 10		
	Finasteride	98319-26-7	Acute toxicity (Oral), Category 4 Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Oral) (Tes- tis), Category 1 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard, Category 1	>= 1 -< 2,5		
	Titanium dioxide	13463-67-7	Carcinogenicity (Inha- lation), Category 2	>= 0,1 -< 1		

SDS Number:

49629-00023

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes.



Version 9.1	Revision Date: 30.09.2023	SDS Number: 49629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
		Get medical a	
		Wash clothing	
	•	0,	ean shoes before reuse.
In cas	se of eye contact	: If in eyes, rins	
			ttention if irritation develops and persists.
If swa	allowed		DO NOT induce vomiting.
		Get medical at	
• • •			horoughly with water.
	important symptoms	, ,	he unborn child.
and e delay	ffects, both acute and ed	May cause da exposure if sw	mage to organs through prolonged or repeated vallowed.
		Contact with d the skin.	lust can cause mechanical irritation or drying of
		Dust contact v	vith the eyes can lead to mechanical irritation.
Prote	ction of first-aiders	: First Aid respo and use the re	onders should pay attention to self-protection, ecommended personal protective equipment ntial for exposure exists (see section 8).
Notes	s to physician		natically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.



Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	49629-00023	Date of first issue: 26.01.2015
	ods and materials for ainment and cleaning up	container for disp Avoid dispersal of with compressed Dust deposits she surfaces, as thes released into the Local or national disposal of this m employed in the of determine which Sections 13 and	f dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust
Advice on safe handling	 ventilation. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the
Hygiene measures	 environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	 Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types:



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	49629-00023	Date of first issue: 26.01.2015
		Strong oxidizin Self-reactive s Organic peroxi Explosives Gases	ubstances and mixtures

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ingredients with workplace control parameters				
Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Finasteride	98319-26-7	TWA	0.5 μg/m3 (OEB 5)	Internal
		Wipe limit	5 µg/100 cm ²	Internal
Titanium dioxide	13463-67-7	TWA (Respirable particulate matter)	2,5 mg/m ³ (Titanium dioxide)	ACGIH

Ingredients with workplace control parameters

This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures	:	Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.
Personal protective equipme	ent	
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Eye protection	:	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a



Version 9.1	Revision Date: 30.09.2023	-	S Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
Skin a	nd body protection	:	aerosols. Work uniform or la Additional body g task being perforr disposable suits)	arments should be used based upon the ned (e.g., sleevelets, apron, gauntlets, to avoid exposed skin surfaces. degowning techniques to remove potentially
SECTION 9	9. PHYSICAL AND CHI	ΞΜΙΟ	CAL PROPERTIES	S
Appea	rance	:	powder	
Color		:	tan	
Odor		:	odorless	
Odor T	Threshold	:	No data available	9
рН		:	No data available	9
Melting	g point/freezing point	:	No data available	e
Initial b range	poiling point and boiling	:	No data available	e
Flash p	point	:	Not applicable	
Evapo	ration rate	:	Not applicable	
Flamm	nability (solid, gas)	:	May form explosing the second	ive dust-air mixture during processing, r means.
Flamm	nability (liquids)	:	No data available	9
	explosion limit / Upper ability limit	:	No data available	e
	explosion limit / Lower ability limit	:	No data available	9
Vapor	pressure	:	Not applicable	
Relativ	ve vapor density	:	Not applicable	
Relativ	ve density	:	No data available	9
Densit	у	:	No data available	9
	lity(ies) ter solubility	:	No data available	e
	on coefficient: n- I/water	:	log Pow: 3,5 pH: 7 Active ingredient	



Finasteride (1%) Formulation

Version	Revision Date:	SDS Nu		Date of last issue: 04.04.2023
9.1	30.09.2023	49629-0		Date of first issue: 26.01.2015
J	nition temperature		data availabl data availabl	-
	sity cosity, kinematic sive properties		applicable explosive	
Oxidiz	ing properties		substance c	r mixture is not classified as oxidizing.
Particl	e size		data available	e

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	Not classified as a re Stable under normal May form explosive on nandling or other me Can react with strong	conditions. dust-air mixture during processing, ans.
Conditions to avoid	Heat, flames and spa Avoid dust formation	
Incompatible materials	Oxidizing agents	
Hazardous decomposition products	No hazardous decon	nposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity		
Not classified based on availa	ble	information.
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
Components:		
Cellulose:		
Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg



sion	Revision Date: 30.09.2023		DS Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
Starc	h:			
Acute	e oral toxicity	:	LD50 (Rat): >	5.000 mg/kg
Acute	e dermal toxicity	:	LD50 (Rabbit):	> 2.000 mg/kg
Finas	steride:			
Acute	e oral toxicity	:	LD50 (Rat): 37	'3 - 828 mg/kg
			LD50 (Mouse)	: 486 mg/kg
Titan	ium dioxide:			
	e oral toxicity	:	LD50 (Rat): >	5.000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > Exposure time Test atmosphe Assessment: T tion toxicity	: 4 h
-	corrosion/irritation lassified based on ava	ailable	information.	
Not cl <u>Com</u> Finas	lassified based on ava ponents: steride:	ailable	information.	
Not c Com	lassified based on ava ponents: steride: ies	ailable : :	information. Rabbit No skin irritatic	n
Not c Com Finas Speci Resu	lassified based on ava ponents: steride: ies	ailable : :	Rabbit	n
Not c Com Finas Speci Resu	lassified based on ava ponents: steride: ies lt ium dioxide: ies	ailable : : :	Rabbit	
Not c Com Finas Speci Resu Titan Speci Resu	lassified based on ava ponents: steride: ies lt ium dioxide: ies		Rabbit No skin irritatic Rabbit No skin irritatic	
Not c Com Finas Speci Resu Titan Speci Resu Serio	lassified based on ava ponents: steride: ies lt ium dioxide: ies lt	: : irritati	Rabbit No skin irritatic Rabbit No skin irritatic	
Not c Com Finas Speci Resu Titan Speci Resu Serio Not c	lassified based on ava ponents: steride: ies it ium dioxide: ies it	: : irritati	Rabbit No skin irritatic Rabbit No skin irritatic	
Not c Com Finas Speci Resu Titan Speci Resu Serio Not c Com Starc	lassified based on ava ponents: steride: ies It ium dioxide: ies It pus eye damage/eye lassified based on ava ponents: th:	: : irritati	Rabbit No skin irritatic Rabbit No skin irritatic	
Not c Com Finas Speci Resu Titan Speci Resu Serio Not c Com	lassified based on ava ponents: steride: ies it ium dioxide: ies it pus eye damage/eye lassified based on ava ponents: th: ies	: : irritati	Rabbit No skin irritatic Rabbit No skin irritatic	n
Not cl Com Finas Speci Resu Titan Speci Resu Serio Not cl Com Starc Speci Resu	lassified based on ava ponents: steride: ies it ium dioxide: ies it pus eye damage/eye lassified based on ava ponents: th: ies	: : irritati	Rabbit No skin irritatio Rabbit No skin irritatio	n
Not cl Com Finas Speci Resu Titan Speci Resu Serio Not cl Com Starc Speci Resu	lassified based on ava ponents: steride: ies it ium dioxide: ies it ous eye damage/eye lassified based on ava ponents: th: ies it steride: ies	: : irritati	Rabbit No skin irritatio Rabbit No skin irritatio	n
Not c Com Finas Specia Resu Titan Specia Resu Serio Not c Com Starc Specia Resu Finas Specia Resu	lassified based on ava ponents: steride: ies it ium dioxide: ies it ous eye damage/eye lassified based on ava ponents: th: ies it steride: ies	: : irritati	Rabbit No skin irritatio Rabbit No skin irritatio information . Rabbit No eye irritatio Rabbit	n



	30.09.2023		S Number: 29-00023	Date of first issue: 26.01.2015
Respi	iratory or skin sens	itization		
Skin	sensitization			
		ailahla in	formation	
INOT CI	assified based on av	allable in	itormation.	
Respi	iratory sensitizatior	า		
Not cl	assified based on av	ailable in	formation.	
Comp	oonents:			
Starc	h:			
Test 1	Tvpe	: 1	Maximization T	est
	s of exposure	: 5	Skin contact	
Speci		: (Guinea pig	
Resul			negative	
Titani	um dioxide:			
Test 7			ocal lymph pa	de assay (LLNA)
			Skin contact	De assay (LLINA)
	s of exposure		Mouse	
Speci Resul			negative	
Carm	coll mutogonicity			
Germ	cell mutagenicity			
		ailable in	formation.	
Not cl	assified based on av	ailable in	formation.	
Not cl		ailable in	formation.	
Not cl <u>Comp</u>	assified based on av ponents:	ailable in	formation.	
Not cl <u>Comp</u> Cellu	assified based on av ponents: lose:			torial roverse mutation assay (AMES)
Not cl <u>Comp</u> Cellu	assified based on av ponents:	: -	Test Type: Bac	terial reverse mutation assay (AMES)
Not cl <u>Comp</u> Cellu	assified based on av ponents: lose:	: -		
Not cl <u>Comp</u> Cellu	assified based on av ponents: lose:	: ⁻	Test Type: Bac Result: negative	9
Not cl <u>Comp</u> Cellu	assified based on av ponents: lose:	: - 	Test Type: Bac Result: negative	e tro mammalian cell gene mutation test
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - - -	Test Type: Bac Result: negative Test Type: In vi Result: negative	e tro mammalian cell gene mutation test e
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose:	: - - - -	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - - - : -	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi ay)
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - - - : - (Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi ay) e
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - 	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi ay) e ite: Ingestion
Not cl <u>Comr</u> Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - 	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi ay) e ite: Ingestion
Not cl Comp Cellul Genot	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo	: - 	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vi ay) e ite: Ingestion e
Not cl Comp Cellul Genot	assified based on av ponents: lose: toxicity in vitro	: - 	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vir ay) e ite: Ingestion e terial reverse mutation assay (AMES)
Not cl Comp Cellul Genot Genot	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro	: - 	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Test Type: Bac	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vir ay) e ite: Ingestion e terial reverse mutation assay (AMES)
Not cl Comp Cellul Genot Starc Genot Finas	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro teride:	: - - - - - - - - - - - - - - - - - - -	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Result: negative	tro mammalian cell gene mutation test mmalian erythrocyte micronucleus test (in vir ay) tte: Ingestion e terial reverse mutation assay (AMES)
Not cl Comp Cellul Genot Starc Genot Finas	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro	: - - - - - - - - - - - - - - - - - - -	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Result: negative	e tro mammalian cell gene mutation test e nmalian erythrocyte micronucleus test (in vir ay) e ite: Ingestion e terial reverse mutation assay (AMES)
Not cl Comp Cellul Genot Starc Genot Finas	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro teride:	: - - - - - - - - - -	Test Type: Bac Result: negative Result: negative Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Test Type: Bac Result: negative Test Type: Chro Result: positive Test Type: In vi	tro mammalian cell gene mutation test mmalian erythrocyte micronucleus test (in vir ay) te: Ingestion terial reverse mutation assay (AMES) e bomosome aberration test in vitro tro mammalian cell gene mutation test
Not cl Comp Cellul Genot Starc Genot Finas	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro teride:	: - - - - - - - - - -	Test Type: Bac Result: negative Result: negative Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Result: negative Test Type: Bac Result: negative Result: negative	tro mammalian cell gene mutation test mmalian erythrocyte micronucleus test (in vir ay) te: Ingestion terial reverse mutation assay (AMES) e bomosome aberration test in vitro tro mammalian cell gene mutation test
Not cl Comp Cellul Genot Starc Genot Finas	assified based on av <u>ponents:</u> lose: toxicity in vitro toxicity in vivo h: toxicity in vitro teride:	: - - - - - - - - - - - - - - - - - - -	Test Type: Bac Result: negative Test Type: In vi Result: negative Test Type: Man cytogenetic ass Species: Mouse Application Rou Result: negative Test Type: Bac Result: negative Test Type: Chro Result: positive Test Type: In vi Result: negative	tro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vir ay) e ite: Ingestion e terial reverse mutation assay (AMES) e omosome aberration test in vitro tro mammalian cell gene mutation test e terial reverse mutation assay (AMES)



rsion	Revision Date: 30.09.2023	SDS Number 49629-00023	
		Test Type Result: ne	e: Alkaline elution assay egative
Genot	toxicity in vivo	cytogene	e: Mutagenicity (in vivo mammalian bone-marrow tic test, chromosomal analysis) on Route: Oral egative
Titani	ium dioxide:		
Geno	toxicity in vitro	: Test Type Result: ne	e: Bacterial reverse mutation assay (AMES) egative
Geno	toxicity in vivo	: Test Type Species: Result: ne	
	nogenicity assified based on av	ailable information	n.
<u>Comp</u>	oonents:		
Cellu	lose:		
	cation Route sure time	: Rat : Ingestion : 72 weeks : negative	
Finas	teride:		
Expos Resul	cation Route sure time t t Organs	: negative : Testes	g body weight
		: Benign tu	
Expos Resul	cation Route sure time t t Organs	: Mouse : Ingestion : 19 month : negative : Testes : Benign tu	(s)
Titani	ium dioxide:		
	cation Route sure time od t	: 2 Years : OECD Te : positive	n (dust/mist/fume) est Guideline 453 nanism or mode of action may not be relevant in h



Versi 9.1	ion	Revision Date: 30.09.2023		9S Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
					is not bioavailable and therefore does not st inhalation hazard.
	Carcino ment	ogenicity - Assess-	:	Limited evidence animals.	of carcinogenicity in inhalation studies with
	-	luctive toxicity mage the unborn child			
9	Compo	onents:			
(Cellulo	se:			
I	Effects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
I	Effects	on fetal development	:	Test Type: Fertility Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
ļ	Finaste	eride:			
I	Effects	on fertility	:	Species: Rabbit Application Route	80 mg/kg body weight
				Species: Rat Application Route Fertility: LOAEL: & Result: positive	y/early embryonic development : Ingestion 30 mg/kg body weight s no evidence that these findings are rele-
I	Effects	on fetal development	:	Species: Rat Application Route Developmental To	o-fetal development : Ingestion oxicity: LOAEL: 0,003 mg/kg body weight ic effects., Embryotoxic effects.
				Species: Monkey Application Route	oxicity: LOAEL: 2 mg/kg body weight
	Reprod sessme	uctive toxicity - As- ent	:	Clear evidence of animal experimen	adverse effects on development, based on ts.



Ver 9.1	sion	Revision Date: 30.09.2023		OS Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015	
		single exposure	ahle	information		
				information.		
	STOT-repeated exposure May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.					
	-	onents:	5 (10	solo) infolgri prolo		
	Finast			Les estres		
		s of exposure Organs sment	:	Ingestion Testis Causes damage exposure.	to organs through prolonged or repeated	
	Repea	ted dose toxicity				
	Comp	onents:				
	Cellulo	ose:				
	Specie		:	Rat		
	NOAE		:	>= 9.000 mg/kg		
		ation Route ure time	:	Ingestion 90 Days		
	Starch					
	Specie		:	Rat		
	NOAE		:	>= 2.000 mg/kg		
		ation Route	:	Skin contact		
	Metho	ure time d	:	28 Days OECD Test Guide	eline 410	
	Finast	eride:				
	Specie	S	:	Rat		
	NOAE	L	:	20 mg/kg		
		- ation Route	:	40 mg/kg Oral		
		ure time	÷	1 y		
		Organs	:	Testis		
	Specie	S	:	Dog		
	NOAE		:	45 mg/kg		
		ation Route ure time	:	Oral 1 y		
		Organs	:	Testis		
	Titaniu	um dioxide:				
	Specie		:	Rat		
	NOAE		:	24.000 mg/kg		
		ation Route ure time	:	Ingestion 28 Days		
			•	20 Days		
	Specie		:	Rat		
	NOAE	L	:	10 mg/m³		



ersion 1	Revision Date: 30.09.2023		0S Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
	cation Route sure time	:	inhalation (dust/m 2 y	ist/fume)
-	ation toxicity assified based on availa	ble	information.	
Expe	rience with human exp	osı	ıre	
Comp	oonents:			
Finas	teride:			
Inges	tion	:	Symptoms: breas tence, lip swelling	t tenderness, breast enlargement, impo- , skin rash
ECTION	12. ECOLOGICAL INFO	DRN	IATION	
Ecoto	oxicity			
Comp	oonents:			
Cellu	lose:			
Toxici	ity to fish	:	Exposure time: 48	ipes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials
Finas	teride:			
Toxici	ity to fish	:	LC50 (Oncorhync Exposure time: 96 Method: FDA 4.1	
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: FDA 4.08	
Toxici plants	ity to algae/aquatic	:	NOEC (Pseudokin mg/l Exposure time: 14 Method: FDA 4.07	
Toxici icity)	ity to fish (Chronic tox-	:	NOEC (Oryzias la Exposure time: 10	tipes (Orange-red killifish)): 0,05 mg/l 05 d
	ity to daphnia and other ic invertebrates (Chron- city)	:	NOEC (Daphnia r Exposure time: 2 ⁻⁷ Method: OECD T	
M-Fac toxicit	ctor (Chronic aquatic y)	:	1	
Titani	ium dioxide:			
Toxici	ity to fish	:	LC50 (Oncorhync Exposure time: 96 Method: OECD T	



ersion 1	Revision Date: 30.09.2023	-	0S Number: 629-00023	Date of last issue: 04.04.2023 Date of first issue: 26.01.2015
	y to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): > 100 mg/l 3 h
Toxicity plants	y to algae/aquatic	:	EC50 (Skeletoner Exposure time: 72	ma costatum (marine diatom)): > 10.000 mg/l 2 h
Toxicity	y to microorganisms	:	EC50: > 1.000 m Exposure time: 3 Method: OECD T	h
Persis	tence and degradabil	ity		
Compo	onents:			
Cellulo	ose:			
Biodeg	radability	:	Result: Readily bi	odegradable.
Finast	eride:			
Biodeg	radability	:	Result: Not readil Biodegradation: Exposure time: 7 Method: FDA 3.1) % d
Stabilit	y in water	:	Hydrolysis: 0 %(5 Method: FDA 3.09	
Bioaco	cumulative potential			
Compo	onents:			
Finast	eride:			
Partitio octano	n coefficient: n- l/water	:	log Pow: 3,57	
	t y in soil a available			
	adverse effects a available			

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	: Do	not dispose of waste into sewer.
	Dis	pose of in accordance with local regulations.
Contaminated packaging	har	pty containers should be taken to an approved waste dling site for recycling or disposal. ot otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations



Finasteride (1%) Formulation

UNR Not re	TDG egulated as a dangerc	us good				
	-DGR egulated as a dangerc	us good				
	IMDG-Code Not regulated as a dangerous good					
	Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.					
Domestic regulation						
	r					
ANT Not re	egulated as a dangero	us 900u				

mixture	gislation specific for the substance of
National List of Carcinogenic Agents for Humans -	(LINACH)
Group 2B: Possibly carcinogenic to humans	
Titanium dioxide	13463-67-7

Titanium dioxide	13463-67-7
Brazil. List of chemicals controlled by the Federal Police	: Not applicable

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	30.09.2023
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Full text of other abbreviations

ACGIH

: USA. ACGIH Threshold Limit Values (TLV)



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
9.1	30.09.2023	49629-00023	Date of first issue: 26.01.2015

ACGIH / TWA

: 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8